Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others
03:44pm, Wednesday, 01'st Feb 2023 Zacks Investment Research
Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
01:50pm, Wednesday, 01'st Feb 2023 Zacks Investment Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Gilead (GILD) Might Surprise This Earnings Season
01:32pm, Wednesday, 01'st Feb 2023 Zacks Investment Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Gilead (GILD) Might Surprise This Earnings Season
09:47am, Wednesday, 01'st Feb 2023
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
03:31pm, Tuesday, 31'st Jan 2023 Zacks Investment Research
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts
11:47am, Tuesday, 31'st Jan 2023 Benzinga
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
Why Gilead (GILD) is Poised to Beat Earnings Estimates Again
05:10pm, Monday, 30'th Jan 2023 Zacks Investment Research
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?
04:03pm, Monday, 30'th Jan 2023 Zacks Investment Research
Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.
Why Gilead (GILD) is Poised to Beat Earnings Estimates Again
01:33pm, Monday, 30'th Jan 2023
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
11:20am, Monday, 30'th Jan 2023 Zacks Investment Research
Style Box ETF report for DVY
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Friday, 27'th Jan 2023
FOSTER CITY, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
03:00pm, Friday, 27'th Jan 2023 Zacks Investment Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eaton Vance Worldwide Health Sciences Fund Adds 3 Stocks to Portfolio
12:53pm, Friday, 27'th Jan 2023
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its equity portfolio for the fourth quarter of 2022 earlier this week.
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
11:20am, Friday, 27'th Jan 2023 Zacks Investment Research
Style Box ETF report for LVHD
Mergers and Acquisitions in 2023 Off To A Strong Start
08:17am, Friday, 27'th Jan 2023
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $
